Important Regulatory Milestone achieved for Immunetune’s NeoVAC platform

Aug 27, 2020

Immunetune is proud to announce that they can continue their regulatory pathway, following supportive Scientific Advice from the Paul-Ehrlich Institute (PEI) in Germany on the 18th of June 2020.

“The overall positive feedback received from the renowned Paul-Ehrlich Institute strengthens Immunetune’s ambitions and path forward to enter clinical testing”, said Dr. Gerben Zondag, CEO and founder of Immunetune. “We are continuing as planned to advance our clinical development program to provide novel, tumor-specific treatment options to cancer patients.” 

The available pre-clinical package (including planned confirmatory experiments and final toxicology study), the CMC / GMP production process as well as the clinical protocol for its synthetic DNA-based cancer vaccines have been thoroughly assessed by PEI experts, and (minor) suggestions and recommendations will be taking into account accordingly.

Immunetune intends to enter the clinic early 2021 with a two-stage phase IIa study in patients with solid tumors to assess the safety and immunogenicity of its synthetic DNA vaccines alone or in combination with checkpoint inhibitors. 

Neoantigen Summit Europe, 20 – 22 April 2021

Neoantigen Summit Europe, 20 – 22 April 2021

Our CEO, Gerben Zondag will present Immunetune's unique platform AmpliVax that enables time- and cost-efficient generation of personalized, DNA-based cancer vaccines at the upcoming digital Neoantigen Summit Europe on 20-22 Apri...

read more
Bio-Europe Spring, 22-25 March 2021

Bio-Europe Spring, 22-25 March 2021

We will attend the digital Bio-Europe Spring patnering meeting on 22 – 25 March 2021. Feel free to request a meeting if you’d like to hear more about possible partnering or investment opportunities.

read more